文献速递神经肿瘤

贝伐珠单抗联合或不联合伏立诺他治疗成人复发胶质母细胞瘤的贝叶斯自适应随机II期多中心试验

A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma.
PubMed 文献 · Neuro Oncol · 2020-01-01

这项多中心II期试验采用贝叶斯自适应设计,将复发胶质母细胞瘤患者随机分配至贝伐珠单抗单药组或贝伐珠单抗联合伏立诺他组,主要终点为无进展生存期。结果显示两组中位无进展生存期(3.7 vs 3.9个月,P=0.94,HR 0.63)和中位总生存期(7.8 vs 9.3个月,P=0.64,HR 0.93)均无显著差异。联合伏立诺他未改善无进展生存期、总生存期或临床获益。

要点

  • 贝伐珠单抗联合伏立诺他组与贝伐珠单抗单药组的中位无进展生存期分别为3.7个月和3.9个月(P=0.94)。
  • 两组中位总生存期分别为7.8个月和9.3个月(P=0.64),临床获益相似。
  • 该试验首次在原发性脑肿瘤患者中验证贝叶斯自适应设计的多中心可行性。

核心结论

  • 贝伐珠单抗联合伏立诺他相比贝伐珠单抗单药未改善复发胶质母细胞瘤成人患者的无进展生存期、总生存期或临床获益。
  • 该试验首次在原发性脑肿瘤患者中测试贝叶斯自适应设计与自适应随机化及贝叶斯连续监测,并证明在多中心环境中使用复杂贝叶斯自适应设计的可行性。

研究设计与样本

  • 多中心II期试验,采用贝叶斯自适应设计,将复发胶质母细胞瘤患者随机分配至贝伐珠单抗单药组或贝伐珠单抗联合伏立诺他组。
  • 主要终点为无进展生存期,次要终点为总生存期和临床结局评估(MD Anderson症状量表脑肿瘤模块[MDASI-BT])。
  • 纳入标准:年龄≥18岁、组织学确诊的胶质母细胞瘤、既往放疗后复发、器官功能充足、KPS≥60、未接受过贝伐珠单抗或HDAC抑制剂。
  • 共入组90例患者(贝伐珠单抗联合伏立诺他组49例,贝伐珠单抗单药组41例),其中74例可评估无进展生存期(联合组44例,单药组30例)。

主要发现

  • 中位无进展生存期:贝伐珠单抗联合伏立诺他组3.7个月 vs 贝伐珠单抗单药组3.9个月(P=0.94,HR 0.63 [95% CI: 0.38, 1.06,P=0.08])。
  • 中位总生存期:贝伐珠单抗联合伏立诺他组7.8个月 vs 贝伐珠单抗单药组9.3个月(P=0.64,HR 0.93 [95% CI: 0.5, 1.6,P=0.79])。
  • 两组临床获益相似。
  • 85例可评估患者中,≥3级毒性包括高血压(n=37)、神经系统改变(n=2)、厌食(n=2)、感染(n=9)、伤口裂开(n=2)、深静脉血栓/肺栓塞(n=2)和结肠穿孔(n=1)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bevacizumab has promising activity against recurrent glioblastoma (GBM). However, acquired resistance to this agent results in tumor recurrence. We hypothesized that vorinostat, a histone deacetylase (HDAC) inhibitor with anti-angiogenic effects, would prevent acquired resistance to bevacizumab. METHODS: This multicenter phase II trial used a Bayesian adaptive design to randomize patients with recurrent GBM to bevacizumab alone or bevacizumab plus vorinostat with the primary endpoint of progression-free survival (PFS) and secondary endpoints of overall survival (OS) and clinical outcomes assessment (MD Anderson Symptom Inventory Brain Tumor module [MDASI-BT]). Eligible patients were adults (≥18 y) with histologically confirmed GBM recurrent after prior radiation therapy, with adequate organ function, KPS ≥60, and no prior bevacizumab or HDAC inhibitors. RESULTS: Ninety patients (bevacizumab + vorinostat: 49, bevacizumab: 41) were enrolled, of whom 74 were evaluable for PFS (bevacizumab + vorinostat: 44, bevacizumab: 30). Median PFS (3.7 vs 3.9 mo, P = 0.94, hazard ratio [HR] 0.63 [95% CI: 0.38, 1.06, P = 0.08]), median OS (7.8 vs 9.3 mo, P = 0.64, HR 0.93 [95% CI: 0.5, 1.6, P = 0.79]) and clinical benefit were similar between the 2 arms. Toxicity (grade ≥3) in 85 evaluable patients included hypertension (n = 37), neurological changes (n = 2), anorexia (n = 2), infections (n = 9), wound dehiscence (n = 2), deep vein thrombosis/pulmonary embolism (n = 2), and colonic perforation (n = 1). CONCLUSIONS: Bevacizumab combined with vorinostat did not yield improvement in PFS or OS or clinical benefit compared with bevacizumab alone or a clinical benefit in adults with recurrent GBM. This trial is the first to test a Bayesian adaptive design with adaptive randomization and Bayesian continuous monitoring in patients with primary brain tumor and demonstrates the feasibility of using complex Bayesian adaptive design in a multicenter setting.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Puduvalli VK, Wu J, Yuan Y, et al. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 2020. PMID: 32166308. doi:10.1093/neuonc/noaa062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。